Some of the key companies, such as Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceutical Development & Commercialization, Inc., Bionomics Limited, and others, are actively working in the PTSD therapeutics market.
DelveInsight’s “Post-Traumatic Stress Disorder Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Post-Traumatic Stress Disorder market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Post-Traumatic Stress Disorder market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Post-Traumatic Stress Disorder: An Overview
Post-traumatic stress disorder (PTSD) has been described as “the complex somatic, cognitive, affective, and behavioral effects of psychological trauma.” It is characterized by intrusive thoughts, nightmares, and flashbacks of past traumatic events, avoidance of trauma reminders, hypervigilance, and sleep disturbance, all of which lead to considerable social, occupational, and interpersonal dysfunction.
PTSD symptoms may start within 1 month of a traumatic event, but sometimes symptoms may not appear for years after. These symptoms cause significant problems in social or work situations and relationships. They can also interfere with the ability to go about the normal daily tasks, and the symptoms are generally grouped into four types: intrusive memories, avoidance, negative changes in thinking and mood, and changes in physical and emotional reactions. Symptoms can vary over time or vary from person to person. Patients can develop PTSD when they go through, see, or learn about an event involving actual or threatened death or serious injury.
Post-Traumatic Stress Disorder Market Key Facts
-
In 2021, the total Post-Traumatic Stress Disorder (PTSD) market size was USD 1,740.2 million, which is expected to rise during the study period (2019–2032).
-
The total market size of Post-Traumatic Stress Disorder (PTSD) in the United States was USD 1,549.9 million in 2021.
-
In EU5, the total market size of Post-Traumatic Stress Disorder (PTSD) was USD 163.4 million in 2021.
-
In Japan, the total market size of Post-Traumatic Stress Disorder (PTSD) was USD 26.9 million in 2021, which is expected to rise during the study period (2019–2032).
-
In the year 2021, the total diagnosed prevalent cases of Post-Traumatic Stress Disorder (PTSD) was 5,340,000+ cases in the 7MM, which is expected to grow during the study period, i.e., 2019–2032.
-
Key players, such as Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceutical, and Bionomics Limited, are involved in the development of the treatment of PTSD.
Post-Traumatic Stress Disorder Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Post-Traumatic Stress Disorder market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Post-Traumatic Stress Disorder market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Post-Traumatic Stress Disorder Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Post-Traumatic Stress Disorder (PTSD) Epidemiology, Segmented by-
-
Total Treated cases of PTSD in the 7MM (2019–2032)
-
Prevalence population of PTSD in the 7MM (2019–2032)
-
Diagnosed prevalent Cases of PTSD in the 7MM (2019–2032)
-
Severity-specific Cases of PTSD in the 7MM (2019–2032)
-
Gender-specific Cases of PTSD in the 7MM (2019–2032)
-
Age-specific Cases of PTSD in the 7MM (2019–2032)
Post-Traumatic Stress Disorder Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Post-Traumatic Stress Disorder market or expected to be launched during the study period. The analysis covers the Post-Traumatic Stress Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Post-Traumatic Stress Disorder pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Post-Traumatic Stress Disorder Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-market
Post-Traumatic Stress Disorder Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Post-traumatic stress disorders. Currently, Otsuka Pharmaceutical Development & Commercialization is leading the therapeutics market with its Post-traumatic stress disorders drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Include:
-
Alto Neuroscience
-
Aptinyx
-
AstraZeneca
-
Bionomics Limited
-
Boehringer Ingelheim
-
GlaxoSmithKline
-
H. Lundbeck A/S
-
Jazz Pharmaceuticals
-
Nobilis Therapeutics
-
Otsuka Pharmaceutical Development & Commercialization, Inc.
-
Pfizer
-
Remedy
-
Sage Therapeutics
-
Tonix Pharmaceuticals, Inc.
-
Yale University
And Many More
Post-Traumatic Stress Disorder (PTSD) Therapies Covered in the Report Include:
-
NBTX-001 Xenon Inhaler: Nobilis Therapeutics
-
Lu AG06466: H. Lundbeck A/S
-
JZP150: Jazz Pharmaceuticals
-
NYX-783: Aptinyx
-
BNC210: Bionomics Limited
-
Brexpiprazole: Otsuka Pharmaceutical Development & Commercialization
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Post-Traumatic Stress Disorder Competitive Intelligence Analysis
4. Post-Traumatic Stress Disorder Market Overview at a Glance
5. Post-Traumatic Stress Disorder Disease Background and Overview
6. Post-Traumatic Stress Disorder Patient Journey
7. Post-Traumatic Stress Disorder Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Post-Traumatic Stress Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Post-Traumatic Stress Disorder Unmet Needs
10. Key Endpoints of Post-Traumatic Stress Disorder Treatment
11. Post-Traumatic Stress Disorder Marketed Products
12. Post-Traumatic Stress Disorder Emerging Drugs and Latest Therapeutic Advances
13. Post-Traumatic Stress Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Post-Traumatic Stress Disorder Market Outlook (In US, EU5, and Japan)
16. Post-Traumatic Stress Disorder Access and Reimbursement Overview
17. KOL Views on the Post-Traumatic Stress Disorder Market
18. Post-Traumatic Stress Disorder Market Drivers
19. Post-Traumatic Stress Disorder Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-market
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/